Impedimed Limited · ASX:IPD
Impedimed — Q4 FY24 Earnings Presentation
26 slides from Impedimed's earnings presentation, Jul 29, 2024
Slide 1: ASX announcement: Investor Presentation
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 29 July 2024 For personal use only Companies Announcements Office Australian Securities Exchange Investor Presentation ImpediMed Limited (ASX:IPD) releases the attached presentation
Slide 2: Investor Presentation: Q4 FY24 results and strategy update
For personal use only Investor Presentation Q4 FY24 results and strategy update July 2024 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. 1
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s For personal use only beliefs, assumptions and expectations and on information currently available to management. All statements that address o
Slide 4: We are gaining momentum on our new strategy: Executive Summary
We are gaining momentum on our new strategy Executive Summary For personal use only 1 We retain leadership in the valuable BIS market 2 New Board and Executive Team set on new strategy and driving growth 3 Financials (revenues and costs) heading in right direction 3
Slide 5: FY24 Q4 highlights
We are gaining momentum on our new strategy FY24 Q4 highlights For personal use only 1 Leads are growing and converting into sales 2 Actions have been taken to manage cash burn FY25 operating cash expenditure In Q4 FY24: forecast to be 10% lower vs FY24 • 38 SOZO units sold and refocused on sales gr
Slide 6: ImpediMed's leadership in the BIS market
For personal use only 1 ImpediMed’s leadership in the BIS market 5
Slide 7: ImpediMed: market leader in BIS
ImpediMed: market leader in BIS For personal use only • ImpediMed offers bioimpedance spectroscopy (BIS) to assess and monitor the fluid status and tissue composition in patients. • Our primary focus is breast cancer-related lymphoedema (BCRL), to reduce its devastating quality-of-life burden and av
Slide 8: SOZO: one non-invasive device, potential applications
SOZO®: one non-invasive device, potential applications For personal use only A single SOZO One device, measurement provides: multiple FDA cleared applications • L-Dex® lymphoedema analysis • Lymphoedema – • HF-Dex® heart failure analysis FDA clearance, CE Mark • Body CompTM • Body composition – • Hy
Slide 9: BIS has strong advantages over traditional measures
BIS has strong advantages over traditional measures For personal use only SOZO non-invasively measures, Advantages of BIS technology monitors and manages fluid status and tissue composition • Level I Randomised Data with Early Intervention in Breast Cancer Patients1 • FDA clearance for lymphoedema a
Slide 10: BIS is used by multiple healthcare providers across the Patient Journey
BIS is used by multiple healthcare providers to manage lymphoedema at each stage of the Patient Journey towards Survivorship For personal use only 1,100 members of the American Society for Reconstructive Microsurgery (ASRM)6 1400 Commission on Cancer (CoC)- accredited Cancer Programs in the US, accr
Slide 11: Early detection has been shown to reduce lymphoedema rates and costs
Early detection has been shown to reduce lymphoedema rates and costs in PREVENT trial and in recent Real-World Evidence (RWE) Global Prevent Trial: 1200 patient Australia NSW Statewide US RWE: Lower progression to For personal use only trial: Lower progression to Lymphoedema Prevention: Economic chr
Slide 12: Australian economic evaluation shows health system ROI of 712%
Australian economic evaluation shows a health system ROI of 712% and significant patient benefits from a Lymphoedema Prevention Program New South Wales Health, Australia Lymphedema Prevention Patient and Clinician Experience Program Economic Appraisal (Feb 2021 – June 20241) “Overall, the patient an
Slide 13: Addressing the Cost Burden of Breast Cancer Related Lymphedema in the US
In the US, addressing the Cost Burden of Breast Cancer Related Lymphedema can generate significant health system and patient savings For every 100 patients monitored with The research shows: BIS instead of tape measure: For personal use only ~20% of patients will develop lymphedema1 11 fewer get chr
Slide 14: A number of guidelines support early detection with BIS
A number of guidelines support early detection with BIS National Comprehensive Cancer Network (NCCN®) American Society of Breast Surgeons NCCN For personal use only For patients and survivors at risk for lymphedema: For breast cancer patients: • Recommends regular lymphedema screening for • Recommen
Slide 15: New team and strategy is now well set
For personal use only 2 New team and strategy is now well set 14
Slide 16: Our new team has breadth of experience and proven track records
Our new team has breadth of experience and proven track records US healthcare market Medtech commercialisation Sales execution Creating long-term value For personal use only Executive Directors Executives Dr Parmjot Bains McGregor Grant Andrew Grant Steven Chen, MD Tim Benkovic Dennis Schlah
Slide 17: Our Board added Non-executive Director Fiona Bones
Our Board added Non-executive Director Fiona Bones, who Chairs our Audit and Risk Management Committee Governance Project delivery Culture Performance For personal use only Christine Emmanuel-Donnelly Janelle Delaney Fiona Bones Non-Executive Chair Non-Executive Director Non-Executive Direct
Slide 18: Immediate priority is focused sales, marketing and clinical execution
Immediate priority is focused sales, marketing and clinical execution ImpediMed 12-Month Priorities For personal use only Next 12 months: Execute towards break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-class customer Break even Expand reac
Slide 19: Raising the awareness of Lymphoedema to support clinical adoption
We are raising the awareness of Lymphoedema to support clinical adoption and patient impact Medical Webinars ImpediMed in the News: Q4 For personal use only Patient Education Podcasts Key Publications: Q4 18
Slide 20: Our 2-year strategy eyes adjacent markets
Our 2-year strategy eyes adjacent markets ImpediMed 2-Year Priorities For personal use only Next 12 months: Execute to break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-class customer Break even Expand reach in Develop new markets execution
Slide 21: Financials are heading in the right direction
For personal use only 3 Financials are heading in the right direction 20
Slide 22: Growing Installed Base with Key US Accounts
Growing Installed Base with Key US Accounts with multi-system expansions U.S. For personal use only US Q4 Key IDN Expansions Global Installed Base . Texas oncology group expansion with 6 devices to 8 in total. . National plastics and breast surgical group 3 initial pilot SOZO’s Dec 23’ expanded with
Slide 23: Increased Installed Base and utilisation driving Patient Testing
Both increased Installed Base and utilisation driving increased Patient Testing SOZO Patient Tests (000s) For personal use only 21% 3-year CAGR 1 21% 3-year CAGR1 Q4 FY24 patient tests up 6% versus Q3 FY24 1.Compound Annual Growth Rate 22
Slide 24: Revenue Metrics: Continuing growth in ARR and low Churn
Revenue Metrics: Continuing growth in ARR and low Churn For personal use only Revenue Core Business TCV1 Core Business ARR2 Churn3 <3% Churn Rate based on SOZO Systems globally 1.Total Contracted Value (TCV) includes any consideration for the sale of SOZO Systems as well as the total Software-as-a S
Slide 25: Cash at end of Q4 is $24.6 million
Cash at end of Q4 is $24.6 million, with FY25 cash costs forecast to be 10% lower vs FY241 Summarized cash flow FY24 For personal use only In thousands AUD Q1 Q2 Q3 Q4 FY Cash at beginning of period 45,710 42,398 36,905 30,682 45,710 Net cash flow from operating activities (3,138) (3,636) (6,278) (4
Slide 26: For personal use only
impedimed’ Ajuo asn jeuosiad 4104 25